IL-6 antagonists to replace systemic corticosteroids as the preferred anti-inflammatory therapy in patients with COVID-19?-Reference-Cited by-同舟云学术

IL-6 antagonists to replace systemic corticosteroids as the preferred anti-inflammatory therapy in patients with COVID-19?

Published:2022-01 Issue: Volume:149 Page:155730
ISSN:1043-4666
Container-title:Cytokine
language:en
Short-container-title:Cytokine

Author:

Kow Chia Siang,Zaihan Abdullah Faiz,Ramachandram Dinesh Sangarran,Hasan Syed Shahzad

Publisher

Elsevier BV

Subject

Molecular Biology,Hematology,Biochemistry,Immunology,Immunology and Allergy

Reference11 articles.

1. The effect of tocilizumab on mortality in hospitalized patients with COVID-19: a meta-analysis of randomized controlled trials;Kow;Eur. J. Clin. Pharmacol.,2021

2. Association between administration of IL-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis;WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group;JAMA,2021

3. Does methylprednisolone reduce the mortality risk in hospitalized COVID-19 patients? A meta-analysis of randomized control trials;Hasan;Expert Rev. Respir. Med.,2021

4. Association between administration of systemic corticosteroids and mortality among critically Ill patients with COVID-19: A meta-analysis;WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group;JAMA,2020

5. Corticosteroid-related in-hospital hyperglycemia: does it negate mortality benefits in COVID-19?;Kow;Clin. Infect. Dis.,2020

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure;Revista Clínica Española (English Edition);2022-05

2. Glucocorticoid therapy in patients with COVID-19 and concurrent heart failure;REV CLIN ESP;2022

3. Tratamiento con glucocorticoides en pacientes con COVID-19 e insuficiencia cardíaca concurrente;Revista Clínica Española;2021-11